Enovis (ENOV) vs Materion (MTRN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Materion (MTRN) has outperformed Enovis (ENOV) over the past year, gaining 55.3% versus a loss of 11.5%. Over five years, MTRN leads with a +108.4% price change compared with -69.5% for ENOV. Materion is the larger company by market cap ($3.81 billion vs $1.47 billion), about 2.6 times the size, while Enovis is growing revenue faster (+6.7% vs +6.0%).
On valuation, Enovis trades at a lower forward P/E (7.4x vs 20.7x for Materion). Materion pays a dividend yielding 0.31%, while Enovis does not currently pay one. Materion converts more of its revenue into profit, with a net margin of 4.2% versus -52.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENOV | MTRN |
|---|---|---|
| Share price | $25.47 | $182.47 |
| Market cap | $1.47B | $3.81B |
| 1-day change | -2.90% | -10.02% |
| YTD return | -4.39% | +46.77% |
| 1-year return | -11.47% | +55.33% |
| 5-year return | -69.49% | +108.37% |
| P/E ratio (TTM) | — | 37.39 |
| Forward P/E | 7.35 | 20.72 |
| EPS (TTM) | $-9.23 | $4.88 |
| Dividend yield | 0.00% | 0.31% |
| Annual dividend | $0.00 | $0.57 |
| Revenue (latest FY) | $2.25B | $1.79B |
| Revenue growth (YoY) | +6.66% | +6.04% |
| Net income (latest FY) | $-1.18B | $74.82M |
| Gross margin | 59.84% | 17.27% |
| Operating margin | -50.01% | 6.15% |
| Net margin | -52.69% | 4.19% |
| 52-week high | $31.67 | $324.99 |
| 52-week low | $16.70 | $116.02 |
| Distance from 52-week high | -19.58% | -43.85% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +48.53% | +44.96% |
| Average volume | 1.71M | 248.26K |
| Shares outstanding | 57.69M | 20.86M |
| Employees | 7,802 | 3,000 |
| Sector | Health Care | Industrials |
| Industry | Industrial Specialties | Industrial Specialties |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Materion is about 2.6 times larger than Enovis by market value ($3.81B vs $1.47B).
- MTRN has outperformed ENOV by 66.8 percentage points over the past year.
- Materion is more profitable, keeping 4.2 cents of every revenue dollar as net income versus -52.7 cents for Enovis.
- The two companies sit in different sectors: Enovis in Health Care and Materion in Industrials.
About Enovis
ENOV stock →Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments.
Health Care · Industrial Specialties · 7,802 employees
About Materion
MTRN stock →Materion Corporation, together with its subsidiaries, produces advanced engineered materials in the United States, Asia, Europe, and internationally. The company operates in four segments: Performance Materials, Electronic Materials, Precision Optics, and Other.
Industrials · Industrial Specialties · 3,000 employees
ENOV vs MTRN FAQ
Which is bigger, Enovis or Materion?
Materion (MTRN) is larger, with a market capitalization of $3.81B compared with $1.47B for Enovis (ENOV).
Which stock has performed better over the past year, ENOV or MTRN?
MTRN returned +55.33% over the past 12 months, compared with -11.47% for ENOV (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Enovis or Materion?
Materion pays a dividend yielding 0.31%, while Enovis does not currently pay a regular dividend.
Are Enovis and Materion in the same industry?
Yes. Both are classified in the Industrial Specialties industry within the Health Care sector.